Executive Summary

Swiss pharmaceutical corporation Roche opened its new Institute for Human Biology in Basel on April 12, 2026, as a sign of investment strength. However, the company faces massive pressure: US President Trump is demanding lower drug prices and threatening tariffs. In response, Roche plans 50 billion dollars in US investments through 2029. In parallel, pressure is mounting in Switzerland through the OECD minimum tax and planned referendums on population caps. The pharmaceutical industry is central to the Swiss economy: it generates 40 percent of economic growth and 41 percent of exports.

People

Topics

  • Swiss pharmaceutical industry
  • US trade policy under Trump
  • Drug price regulation
  • Location attractiveness
  • Tax burden on multinational corporations

Clarus Lead

Roche's investment is a political signal in critical times. Trump is forcing the global pharmaceutical industry to redistribute: massive US investments are meant to ward off tariff penalties, while Switzerland is losing attractiveness as a research location. At the same time, the OECD minimum tax and the planned SVP initiative on population caps threaten competitiveness. The industry is signaling: without political support, there is a risk of capital and talent flight – with significant consequences for prosperity and jobs in Switzerland.

Detailed Summary

The structural imbalance is remarkable: Roche invests 41 billion Swiss francs in Switzerland but generates only one percent of its revenue there. In the US, revenue share is 48 percent – with total investments of 64 billion francs to date (2016–2025). Schinecker puts this bluntly: "50 percent of all employees here at this location are paid by the money we earn in the US." The planned 50 billion dollars through 2029 intensifies this asymmetry.

Trump's letter to pharmaceutical companies (addressed to AstraZeneca, Merck, Pfizer, Novo Nordisk, Genentech, and Novartis) demands price parity with Germany and Switzerland. The threat of tariffs as an enforcement tool forces all to react. The industry association Interpharma warns of "geopolitical developments" and "new international rules of the game." China also creates pressure for massive investments in research and production.

Additionally, Switzerland itself has tightened its framework conditions. The OECD minimum tax (15 percent minimum tax rate for corporations with over 750 million euros in revenue) increased the tax burden by 1.9 percentage points. Roche Board President Schwan complains clearly: "We pay more taxes in Switzerland than we have in revenue." Nonetheless: Roche achieved 13.8 billion francs in net profit in 2025 with 61.5 billion francs in revenue. Tax payments increased, with further increases expected in 2026.

Add to this the upcoming popular referendum on the SVP initiative for a population cap (maximum ten million inhabitants; currently 9 million). Such restrictive migration policy threatens Roche's ability to attract international specialists – a critical success factor for a global research company. Federal Councillor Baume-Schneider underscores another point: drug price increases could threaten and would erode social support. She demands: "Affordability and access must be part of innovation."

The new Institute for Human Biology (with space for 250 researchers, part of the 1.4 billion franc investment) is intended to accelerate drug development with AI and bioinformatics. Schinecker emphasizes the risks: only about one in ten developed drugs ultimately reaches patients. In Switzerland alone, 3.5 billion francs flow annually into pharmaceutical research – four times the local revenue.

Key Statements

  • Trump's price threats force Roche and the global pharmaceutical industry to make massive US investments at the expense of other regions
  • Switzerland is losing attractiveness despite its role as a global research center, due to rising taxes and restrictive migration policies
  • The pharmaceutical industry is systemically critical for the Swiss economy (40% economic growth, 41% exports, 50,000 direct jobs), but increasingly endangered by structural shifts

Critical Questions

  1. Evidence/Data Quality: How valid is Schinecker's claim that 50 percent of Swiss employees are financed by US revenue – is this calculation transparently disclosed or based on internal cost allocation models?

  2. Conflicts of Interest: To what extent does the pharmaceutical industry strategically use its economic importance (40% economic growth) for tax breaks, even though Roche still achieved 13.8 billion francs in net profit in 2025?

  3. Causality: Are job cuts (Novartis announced hundreds of positions) actually caused by external pressures (Trump, OECD tax) or by internal efficiency programs and consolidation?

  4. Alternatives: Why was the OECD minimum tax not combined with flanking measures (targeted R&D incentives, tax deductions) instead of being introduced in isolation?

  5. Feasibility: Can restrictive migration limits (SVP initiative) be practically reconciled with Roche's need for international specialists, or does this lead to direct conflict?

  6. Price Consequences: What evidence exists that Roche will raise drug prices – is this a forecast by the Federal Councillor or based on concrete company statements?

Bibliography

Primary Source: "Pharma – 'We Pay More Taxes in Switzerland Than We Have in Revenue'" – Süddeutsche Zeitung, April 12, 2026, https://www.sueddeutsche.de/wirtschaft/pharma-schweiz-roche-usa-trump-li.3453820

Verification Status: ✓ 12.04.2026

This text was created with the assistance of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 12.04.2026